Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 15, 2011 Brian Orelli	Dark Clouds Lift Over Pharma Dispute The case of who bought whom in the Merck -Schering-Plough deal has ended in a draw.
The Motley Fool May 12, 2009 Brian Orelli	Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool July 30, 2010 Brian Orelli	It's Hard to Get Excited About 92% Revenue Growth Especially when revenue dropped on a comparable basis.
The Motley Fool July 21, 2009 Brian Orelli	Merck and Schering: A Less Ugly Bride and Groom Merck and Schering-Plough are up today on "better than expected" earnings, but the bride and groom don't look all that great heading into the wedding.
The Motley Fool April 27, 2009 Brian Orelli	Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA.
The Motley Fool February 16, 2010 Brian Orelli	Merck Gets a Pass, for Now Its first quarter looks promising, but not as good as could be hoped.
The Motley Fool November 4, 2009 Brian Orelli	An Ode to Schering-Plough Mergers and acquisitions in the pharmaceutical industry are cataloged in a poem.
The Motley Fool September 29, 2011 Brian Orelli	Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson.
The Motley Fool March 2, 2010 Brian Orelli	Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off.
The Motley Fool May 29, 2009 Brian Orelli	Merck's Bad News Nothing to Sneeze At The U.S. Patent and Trademark Office reexamination of Merck's patent on allergy medication, Singulair, is nothing to sneeze at. The $2.8 billion worth of Singulair that Merck sold in the U.S. last year made up 12% of its total pharmaceutical sales.
The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
The Motley Fool July 30, 2009 Brian Orelli	Merck, Sanofi, and Schering's Love Triangle Perhaps the most complicated deal of the year.
The Motley Fool February 3, 2011 Brian Orelli	Get Ready for Merck's Bumpy Ride Long-term earnings guidance gets thrown out the window.
The Motley Fool June 30, 2009 Brian Orelli	Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward.
The Motley Fool July 8, 2010 Brian Orelli	Surprise Us in a Good Way, Merck Keeping up productivity during plant closures won't be easy.
The Motley Fool September 3, 2009 Brian Orelli	Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing.
The Motley Fool November 25, 2009 Brian Orelli	A Schizophrenic Move by Merck? Issue $29 billion in shares, buy back $3 billion. Say what? Merck increased its share count by almost 45% to pay for the acquisition of Schering-Plough. Now it's planning to buy some of that stock back.
The Motley Fool August 7, 2009 Brian Orelli	A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court.
The Motley Fool April 21, 2009 Brian Orelli	Schering and Merck: A Match Made in Purgatory Until Merck can show that it's capable of growing sales again, investors should be leery of stepping in, even with the dividend yield pushing 6%.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool April 24, 2008 Brian Orelli	Is Schering-Plough the Comeback Kid? Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs.
The Motley Fool December 5, 2007 Brian Orelli	Merck Stays Conservative Merck sets the bar low with its 2008 guidance. Is the company being overly cautious?
The Motley Fool April 4, 2008 Brian Orelli	Why Is Schering Cutting Now? The latest pharmaceutical company to jump on the cost-cutting bandwagon is Schering-Plough.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
The Motley Fool July 24, 2007 Brian Orelli	No Pharma Love for Schering A doubling of earnings, but no jump in stock price? Schering investors, take note.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool June 30, 2008 Brian Orelli	Merck and Schering Get Half a Divorce The lovey-dovey duo ends their respiratory partnership.
The Motley Fool November 5, 2009 Brian Orelli	Slow Down There, Merck Merck CEO Richard Clark says his company is looking to do more deals than ever, perhaps "even try to double" the current rate of 50 per year.
The Motley Fool April 22, 2008 Brian Orelli	Will Merck Make It? Merck releases first-quarter results and says it can meet its previous guidance.
The Motley Fool May 12, 2010 Brian Orelli	Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong.
The Motley Fool June 30, 2011 Brian Orelli	2 Backdoor Biotech IPOs to Watch Just don't buy yet.
The Motley Fool February 29, 2008 Brian Orelli	Merck's Complicated Partnerships Merck has decided to continue its complicated partnership with AstraZeneca for at least a few more years.
The Motley Fool January 27, 2010 Brian Orelli	Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that.
The Motley Fool December 17, 2009 Brian Orelli	This Acquisition Hears, Smells, and Tastes Soooo Good Johnson & Johnson picks up an ear, nose, and throat medical device maker.
The Motley Fool October 27, 2009 Brian Orelli	Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions?
The Motley Fool November 20, 2009 Brian Orelli	This Baby Is a Nice Addition A month into an acquisition, and Merck already sees a benefit.
The Motley Fool October 13, 2009 Brian Orelli	J&J Needs to Get Drugged Up Medical devices and diagnostics pass by drugs as the main revenue source.
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
The Motley Fool June 4, 2009 Brian Orelli	MegaMergers Going to the Dogs It looks like Merck isn't sure it'll be able to get its acquisition of Schering-Plough past regulators without doing a little trimming.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool May 4, 2010 Brian Orelli	Earnings Growth Trumps Revenue Growth, Except Here A solid quarter for Pfizer, but is there more in the tank?
BusinessWeek October 2, 2006 Gene G. Marcial	Shopping For Schering? The buzz about Schering-Plough on Wall Street is that the company is in play.
The Motley Fool May 18, 2011 Brian Orelli	If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship.
The Motley Fool January 21, 2011 Brian Orelli	Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir.
The Motley Fool October 23, 2009 Brian Orelli	Merck-Schering Doesn't Look So Good Revenue is stagnant; let's hope that pipeline pans out.
The Motley Fool October 23, 2007 Brian Orelli	Schering Ploughed Down Investors punish the pharmaceutical company when it misses Wall Street expectations following 11 consecutive quarters of double-digit sales growth.
The Motley Fool December 14, 2007 Brian Orelli	Panel Kills Merck's Hope of OTC Status An FDA advisory panel isn't convinced that Merck's cholesterol-lowering drug MEVACOR deserves OTC status.
The Motley Fool September 15, 2009 Brian Orelli	What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri.